Best Life Sciences Companies in New Haven, United States
The 51 best Life Sciences companies in New Haven, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biohaven.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in New Haven
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Biohaven Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases 72Funding top 19%News top 27%Growth top 30%Market top 40% All 8 signals ▾Fundingtop 19% Newstop 27% Growthtop 30% Markettop 40% Techtop 40% Fin. healthtop 43% Moatbottom 41% Globalbottom 32% Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 13 BI events in 12 mo (of 43 tracked, 9 types) · +86% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $250M | 15 mo ago | 202 | 2022 | — | Top 5M | — | 1 internship · 1 expansion |
| 2 | Halda Therapeutics Developer of precision therapeutics for cancer treatment | $217M | 23 mo ago | 30 | 2019 | Craig Crews Founder & CEO | Top 10M | — | — |
| 3 | melinta therapeutics Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to… | $186M | 89 mo ago | 162 | 2000 | — | — | 376 patents Novel boronic acid‑based beta‑lactamase inhibitors for treating resistant bacterial infections | — |
| 4 | IsoPlexis Developer of multiplexed single-cell analysis tools for the diagnostics and life science research | $186M | 66 mo ago | 195 | 2012 | — | — | 72 patents High-throughput single-cell capture, secretion profiling, and miniaturized sequencing technologies. | — |
| 5 | NextCure Developer of next-generation immuno-oncology-based drugs 69News top 21%Funding top 23%Patents top 25%Moat top 26% All 11 signals ▾Newstop 21% Fundingtop 23% Patentstop 25% Moattop 26% Growthtop 30% Innovationtop 32% Fin. healthtop 43% Markettop 44% Partnerstop 45% Techbottom 46% Globalbottom 42% News: 7 BI events in 12 mo (of 19 tracked, 5 types) · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $175M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $175M | 8 mo ago | 87 | 2015 | — | Top 10M | 77 patents Novel immune‑checkpoint antibody therapeutics for cancer immunotherapy. | — |
| 6 | Kolltan Pharmaceuticals Using antibody to target different tyrosine kinase receptors to treat cancer. | $141M | 148 mo ago | 41 | 2007 | — | — | — | — |
| 7 | Cybrexa Therapeutics Developer of therapeutics that target the tumour microenvironment | $118M | 49 mo ago | 19 | 2016 | — | Top 50M | — | — |
| 8 | Arvinas Developer of small molecule drugs to target and degrade disease causing proteins | $100M | 84 mo ago | 266 266 → 305 (+15%) | 2013 | — | Top 5M | — | 1 partnership |
| 9 | Transgenomic Molecular Diagnostics in cardiology, oncology, and inherited diseases | $72M | 111 mo ago | 53 | 1997 | — | — | — | — |
| 10 | Simcha Therapeutics Developer of therapeutics with anti-tumor effect | $65M | 13 mo ago | 15 | 2018 | Aaron Ring Founder | Top 50M | — | — |
| 11 | Molecular Staging Transforming detection and measurement of proteins and nucleic acids for life sciences | $50M | 183 mo ago | — | 1998 | Torben Spanget Christensen ex-CEO | — | — | — |
| 12 | Optherion Developer of products to treat age-related macular degeneration | $42M | 202 mo ago | 5 | 2005 | Colin Foster Co-Founder & CEO | — | — | — |
| 13 | Achillion Pioneering new possibilities for the rare disease community through innovative science | $41M | 294 mo ago | 2,372 | 1998 | Milind Deshpande CEO | — | 2 patents Antiviral hepatitis C therapeutics targeting viral replication | — |
| 14 | Ikonisys Developer of non-invasive diagnostic tests for cancer detection | $35M | 17 mo ago | 8 | 1999 | Michael Kilpatrick Founder | — | 235 patents Automated fluorescence microscopy and digital pathology for cancer detection | — |
| 15 | Kleo Pharmaceuticals Developing a new class of immunotherapies utilizing small molecules to activate an individual's own immune… | $35M | 72 mo ago | 20 | 2015 | — | — | — | — |
| 16 | Biorez Synthetic products for soft tissue regeneration of anterior cruciate ligament injuries | $29M | 61 mo ago | 24 | 2008 | — | — | — | — |
| 17 | EpiEP Medical device company specializing in epicardial access systems for minimally invasive procedures | $24M | 92 mo ago | 5 | 2008 | — | — | — | — |
| 18 | Bexorg Developer of whole-brain perfusion model for drug discovery | $23M | 9 mo ago | — | 2021 | Zvonimir Vrselja CEO | Top 50M | 8 patents Advanced organ perfusion systems and ML-driven brain perfusion simulation technologies | 1 partnership |
| 19 | Renetx Bio Company developing first-in-class drugs to treat injuries and damages to the CNS | $13M | 70 mo ago | 7 | 2010 | Stephen Strittmatter Founder | — | — | — |
| 20 | Jumo Health Provider of healthcare education and clinical trial solutions for patients and professionals | $13M | 23 mo ago | 86 | 2009 | Brittany Erana CEO | Top 10M | — | — |
| 21 | Modifi Bio Developer of therapeutics for the treatment of cancer | $12M | 23 mo ago | 11 | 2021 | Ranjit Bindra Co-Founder | — | — | — |
| 22 | Weave AI-powered platform to accelerate investigational new drug submission | $10M | 9 mo ago | 9 | 2022 | Umut Eser Co-Founder & Chief AI Officer | — | — | — |
| 23 | Osmol Therapeutics Developer of treatments for chemotherapy-induced peripheral neuropathy (CIPN) | $8M | 51 mo ago | 2 | 2016 | Barbara Ehrlich Founder | — | — | — |
| 24 | Mira Dx miRNA-based diagnostic tests | $7M | 191 mo ago | 13 13 → 29 (+123%) | 2008 | Joanne Weidhaas Chairperson of the Board and Co-Founder | Top 50M | 44 patents Predictive cancer biomarkers for immunotherapy response and radiation toxicity assessment. | — |
| 25 | Wavelet Developer of fetal brain monitoring technology using electroencephalography and algorithms | $7M | 3 mo ago | — | — | Liz Golden Co-Founder & CEO | — | — | — |
| 26 | Affomix Video playlist creation and sharing platform with feedback and communication features | $7M | 219 mo ago | — | 2006 | — | — | 20 patents High-throughput protein interaction screening and nucleic‑acid scaffolds for antibody specificity. | — |
| 27 | ProteoWise Provider of a platform for the analysis of proteomics | $6M | 19 mo ago | — | 2018 | Mikhail Kostylev Co-Founder | — | 6 patents Multiplexed biomarker capture and analysis platforms for biological samples | — |
| 28 | Artificial Cell Technologies Redefining vaccine manufacturing through rapid, synthetic, and personalized production | $6M | 146 mo ago | 8 | 2006 | Donald Masters CEO | — | 118 patents Particle-based vaccine and drug delivery formulations using layer‑by‑layer coating technologies | — |
| 29 | RxAll AI platform to authenticate medicines & a platform to enable pharmacy procurement | $5M | 60 mo ago | 28 | 2015 | Adebayo Alonge Co-Founder & CEO | Top 50M | — | 5 job openings |
| 30 | Precipio Diagnostics Provider of cancer diagnostics and second opinion tools | $5M | 105 mo ago | 56 | 1997 | — | Top 10M | — | — |
| 31 | Affinimark Technologies Develops diagnostic products for cerebrospinal fluid leaks | Website not working. | $2M | 125 mo ago | 7 | 2007 | Harry Penner Founder & Chairman | — | 12 patents Immunodiagnostic devices for cerebrospinal fluid analysis and disease detection | — |
| 32 | Verinomics Developer of genomic and gene editing platforms for crop improvement | $2M | 16 mo ago | 13 | 2016 | Stephen Dellaporta Founder | — | — | — |
| 33 | AtlasXomics Provider of omics data analysis platform | $2M | 13 mo ago | 22 22 → 22 (+0%) | 2019 | — | Top 10M | 13 patents Microfluidic chiplet platforms enabling high‑throughput spatial omics assays | — |
| 34 | My Gene Counsel Digital genetic counseling platform bridging genetics and precision medicine | $1M | 99 mo ago | 25 | 2014 | — | Top 50M | — | 1 job opening |
| 35 | PiroGon Developer of medical device for the treatment of acid reflux | $1M | 54 mo ago | — | 2021 | Rigu Gupta Founder & CEO | — | — | — |
| 36 | CMDBioscience DNA/RNA synthesis services, modifications, oligos, and related products provider | $925K | 164 mo ago | 6 | 2006 | Joseph Audie Co-Founder & CEO | — | — | — |
| 37 | Prevention Pharmaceuticals Dietary supplement and nutraceutical products | $650K | 186 mo ago | — | 2008 | Terrence Tormey President & CEO | — | — | — |
| 38 | Mifcor Therapeutics Therapies that reduce tissue damage associated with heart attacks, acute kidney injury | $500K | 128 mo ago | — | 2014 | Jernej Godec Co-Founder | — | — | — |
| 39 | KovaDx Provider of an AI based health monitoring and red blood cell diseases diagnostic tool for providers | $256K | 60 mo ago | 5 | 2020 | Yaw Ofosu Ansong CEO | — | 4 patents Nucleic‑acid‑based diagnostic assays for hemolytic anemia and related blood disorders | — |
| 40 | MZ Diagnostics Developer of non-genotypic assays for the detection of antimicrobial resistance | $225K | 163 mo ago | — | 2011 | Michael Hodsdon Co-Founder | — | 94 patents Molecular diagnostic assays using cooperative primers for allele-specific nucleic acid detection | — |
Top 12 Life Sciences companies in New Haven
#1
Public · New Haven, Connecticut · founded 2015 · 87 employees$175.4Mraised▾
Developer of next-generation immuno-oncology-based drugs. The proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. The pipeline candidates include NC318 for tumor and macrophages, NC410 for myeloid and T-cells, NC762 for tumors, NC252 for leukemia cells, and others.
- Nov 2025Post IPO$21.5M
- Nov 2018Series B$93.4M
- Nov 2018Series A$15M
- Jan 2016Series A$67M
#2
Public · New Haven, Connecticut · founded 2022 · 202 employees$250Mraised▾
Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases. The company leverages its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder, and spinocerebellar ataxia and myostatin inhibition for neuromuscular diseases.
- Apr 2025Post IPO$250M
#3
Seed · New Haven, Connecticut$7Mraised▾
Developer of fetal brain monitoring technology using electroencephalography and algorithms. This system utilizes sensors to record brain activity during pregnancy. Machine learning processes the collected data to provide analysis regarding fetal neurological development. The technology functions as a non-invasive tool for healthcare providers to observe brain function and identify potential health issues.
- Apr 2026Seed$7M
#4
Series B · New Haven, Connecticut · founded 2018 · 15 employees$65Mraised▾
Developer of therapeutics with anti-tumor effect. The lead candidate of the company is ST-067, based on the immune system and IL-18 cytokine which is having potent antitumor effects. The company claims to have shown a positive response on the animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors.
- Jun 2025Series B$7.1M
- Jan 2022Series B$40M
- Jun 2020Series A$25M
- Jul 2018Series A$4.4M
#5
Series A · New Haven, Connecticut · founded 2021$23Mraised▾
Developer of whole-brain perfusion model for drug discovery. The company's proprietary technology transforms brains into discovery machines by perfusing whole human and porcine brains, generating highly dimensional datasets consisting of cellular responses.
- Oct 2025Series A$23M
#6
Acquired · New Haven, Connecticut · founded 2019 · 30 employees$216.7Mraised▾
Developer of precision therapeutics for cancer treatment. It offers a lead drug candidate which is a RIPTAC therapeutic that utilizes androgen receptor as a targeting protein to selectively deliver the drug for the treatment of metastatic, castrate-resistant prostate cancer, and tumors.
- Aug 2024Series B$126.5M
- May 2024Series B$24.2M
- Dec 2021Series B$41M
- Feb 2019Series A$25M
#7
Series A · New Haven, Connecticut · founded 2022 · 9 employees$10Mraised▾
AI-powered platform to accelerate investigational new drug submission. The platform accelerate document drafting, navigate complex source documents, streamline reviews, and automatic content updates. It has applications for pharmaceutical companies, biotech, and regulatory consultants.
- Oct 2025Series A$20M
- May 2024Seed$10M
- Aug 2022Seed$1.6M
#8
Public · New Haven, Connecticut · founded 1999 · 8 employees$35.2Mraised▾
Developer of non-invasive diagnostic tests for cancer detection. The company has developed oncoFISH for the detection of cancer-related chromosomal abnormalities, oncoFISH bladder for the diagnosis of bladder cancer, oncoFISH cervical, oncoFISH PTEN, and oncoFISH ALK. Also developed a proprietary Ikoniscope digital microscope to deliver highly accurate and reliable detection of rare cells.
- Feb 2025Post IPO$524.8K
- Nov 2024Post IPO$211.2K
- Dec 2023Post IPO$1.1M
- Jul 2012Series C$1.4M
#9
Seed · New Haven, Connecticut · founded 2019 · 22 employees$1.8Mraised▾
Provider of omics data analysis platform. It offers a drug discovery platform for clinicians and researchers to analyze multi-omics data like transcriptomic, proteomic, and epigenomics.
- Jun 2025Grant (prize money)$400K
- May 2025Grant (prize money)$399.9K
- Jul 2024Grant (prize money)$399.9K
- Mar 2024Grant (prize money)$400K
#10
Series A · New Haven, Connecticut · founded 2009 · 86 employees$12.5Mraised▾
Jumo Health develops educational resources for patients and clinical trial solutions for researchers. The contents on the platform are written by the staff of doctors, peer-reviewed by leading specialists, and endorsed by patient association and advocacy groups and cover a wide range of therapeutic areas, including rare diseases. The platform assists researchers to approach partici[ants for clinical trial and address the patient recruitment process. The company uses visual aids and study protocol for the clinical trial recruitment process.
- Aug 2024PE—
- Aug 2020Series A$2.3M
- Apr 2018Series A$2.5M
- Feb 2015Series A$1.3M
#11
Series A · New Haven, Connecticut · founded 2018$6.3Mraised▾
Proteo Wise involvs in the proteomic analysis. The company's patented product 3 Dimensional Nano Scale Protein Capture (3D-NPC) technology is used for protein analysis. In this technology, the nanoscale material binds with the protein and then with antibody probes to give result.
- Dec 2024Series A$2.3M
- Jun 2020Grant (prize money)$251.9K
- Mar 2020Series A$6.3M
#12
Acquired · New Haven, Connecticut · founded 2021 · 11 employees$11.7Mraised▾
Developer of therapeutics for the treatment of cancer. The company focuses on developing therapeutics that uniquely target specific acquired cancer cell DNA mutations for the treatment of all cancer types.
- Aug 2024Seed$995.5K
- Oct 2023Seed$4.3M
- Jul 2022Seed$6.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.